TFS HealthSciences, a Lund, Sweden-based contract research organization company, acquired Appletree CI Group, a Winterthur, Switzerland-based niche CRO and global regulatory affairs service provider.
The amount of the deal was not disclosed.
The two companies will now offer clients complimentary and expanded service offerings, including a specialized therapeutic focus in ophthalmology with an increased global footprint. The partnership with Appletree will enable TFS to establish a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K.
Led by President and CEO Georg Mathis, Appletree CI Group is an expert niche CRO and global regulatory affairs service provider with track records in ophthalmology and medical device investigations. The company is focused on five primary business areas; in addition to ophthalmology and medical devices, they have expertise in the fields of dermatology, pediatric trials, and regulatory affairs. Appletree works in 11 European countries and have over 30 permanent staff.
Led by CEO Bassem Saleh, TFS HealthScience is a Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process, Strategic Resourcing Solutions (SRS), which offers expert insourcing and targeted recruitment services, and Functional Services (FSP), to provide customers with strategic workforce management solutions.
FinSMEs
23/01/2023